One Stop Shop for All Your Market Research Reports

Global Capecitabine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur. According to our (Global Info Research) latest study, the global Capecitabine market size was valued at USD 1055.9 million in 2022 and is forecast to a readjusted size of USD 1027.9 million by 2029 with a CAGR of -0.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares. This report is a detailed and comprehensive analysis for global Capecitabine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided. Key Features: Global Capecitabine market size and forecasts, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/g), 2018-2029 Global Capecitabine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/g), 2018-2029 Global Capecitabine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/g), 2018-2029 Global Capecitabine market shares of main players, shipments in revenue ($ Million), sales quantity (Kg), and ASP (USD/g), 2018-2023 The Primary Objectives in This Report Are: To determine the size of the total market opportunity of global and key countries To assess the growth potential for Capecitabine To forecast future growth in each product and end-use market To assess competitive factors affecting the marketplace This report profiles key players in the global Capecitabine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Teva, Mylan, Hikma and Hengrui Medicine, etc. This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence. Market Segmentation Capecitabine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets. Market segment by Type 500 mg 150 mg Market segment by Application Breast Cancer Colorectal Cancer Stomach Cancer Major players covered Roche Teva Mylan Hikma Hengrui Medicine Cipla Reliance Group Hetero Market segment by region, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia) South America (Brazil, Argentina, Colombia, and Rest of South America) Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa) The content of the study subjects, includes a total of 15 chapters: Chapter 1, to describe Capecitabine product scope, market overview, market estimation caveats and base year. Chapter 2, to profile the top manufacturers of Capecitabine, with price, sales, revenue and global market share of Capecitabine from 2018 to 2023. Chapter 3, the Capecitabine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Capecitabine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029. Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029. Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Capecitabine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029. Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War. Chapter 13, the key raw materials and key suppliers, and industry chain of Capecitabine. Chapter 14 and 15, to describe Capecitabine sales channel, distributors, customers, research findings and conclusion.
1 Market Overview 1.1 Product Overview and Scope of Capecitabine 1.2 Market Estimation Caveats and Base Year 1.3 Market Analysis by Type 1.3.1 Overview: Global Capecitabine Consumption Value by Type: 2018 Versus 2022 Versus 2029 1.3.2 500 mg 1.3.3 150 mg 1.4 Market Analysis by Application 1.4.1 Overview: Global Capecitabine Consumption Value by Appli
Inquiry Before Buying

Request Sample

Share This Report

Our Clients

Payment Mode
Single User US $ 3480
Multi User US $5220
Corporate User US $6960
About this Report
Report ID 153919
Category
  • Pharmaceuticals and Healthcare
Published on 02-Jan
Number of Pages 92
Publisher Name Global Info Research
Editor Rating
★★★★★
★★★★★
(15)